特朗普政府去年12月与其他九家主要制药公司达成协议，降低政府医疗补助计划和使用现金支付的消费 者的药品价格，旨在使美国的药品价格与其他富裕国家一致。 强生公司周四表示，已经与美国总统特朗普的政府达成协议，将降低美国人的药品价格，以换取美国的 关税豁免。 美国患者目前为处方药支付的费用要高得多，通常是其他发达国家的近三倍，特朗普一直在向制药商施 压，要求他们将价格降至国外支付的水平。 强生公司当地时间周四在一份声明中表示："该联合协议符合特朗普总统向行业提出的要求，并为公司 的制药产品提供了关税豁免。" 协议的具体条款没有披露，包括修订后药品价格的细节，以及涵盖哪些药品。 强生还表示，将加入TrumpRx.gov网站，让美国人以大幅折扣的价格购买其药品。此外，还将以与其他 发达国家相当的价格，为医疗补助计划（Medicaid）提供药品。 根据去年12月达成的协议，所有九家美国制药商都同意降低向低收入人群医疗补助计划（Medicaid）销 售的大部分药品的价格，承诺为常用药物节省"巨额费用"。 强生公司还表示，作为其去年宣布的550亿美元美国投资计划的一部分，将在北卡罗来纳州和宾夕法尼 亚州新建两家生产工厂。 强 ...

Core Viewpoint - Johnson & Johnson (JNJ.US) has reached an agreement with the Trump administration to lower drug prices in exchange for tariff exemptions, following similar agreements by other pharmaceutical companies [1] Group 1: Company Agreements - Johnson & Johnson is the latest pharmaceutical company to agree to lower drug prices, joining GlaxoSmithKline (GSK.US), Merck (MRK.US), and Novartis (NVS.US) [1] - Pfizer (PFE.US) and AstraZeneca (AZN.US) were among the first to agree to reduce prescription drug prices for tariff relief [1] - Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) also reached agreements to significantly lower prices for commonly used GLP-1 weight loss drugs for Medicare, Medicaid, and out-of-pocket patients [1]

Key TakeawaysFormer President Trump announced a White House meeting with the top 14 oil companies tomorrow, following his statements about potentially taking "trillions of dollars worth of oil," particularly from Venezuela after the recent ouster of Nicolás Maduro.China's inflation has accelerated at its fastest pace in nearly three years, primarily driven by higher food costs, while the nation's car exports are set to jump as domestic sales cool.Johnson & Johnson (JNJ) has reached a deal with the U.S. gove ...

Core Viewpoint - The agreement allows Johnson & Johnson's pharmaceutical products to be exempt from tariffs, which may positively impact the company's cost structure and pricing strategy [1] Group 1 - Johnson & Johnson's pharmaceutical products will benefit from tariff exemptions under the new agreement [1]

Authored by Zachary Stieber via The Epoch Times,Bayer and its Monsanto division are suing COVID-19 vaccine manufacturers, alleging they used technology Monsanto developed and patented in the 1980s in their vaccines.Bayer said in lawsuits that Pfizer, its partner BioNTech, and Moderna wrongly used technology Monsanto developed and used to make plants resistant to insects.Pfizer-BioNTech and Moderna included the technology in their shots to enhance the stability of messenger ribonucleic acid (mRNA) “and thus ...

Core Point - Johnson & Johnson has reached an agreement with the U.S. administration to reduce drug prices for Americans in exchange for exemptions from U.S. tariffs [1] Group 1 - The agreement aims to lower drug prices for American consumers [1] - The deal includes tariff exemptions for Johnson & Johnson [1]

强生公司：正在参与特朗普用药计划官网（TrumpRX.gov）的相关事宜。 本文源自：金融界AI电报 ...

Core Viewpoint - Johnson & Johnson has entered a voluntary agreement with the Trump Administration aimed at improving access to medicines and reducing costs for American patients, while also receiving an exemption from tariffs for its pharmaceutical products [1][2]. Group 1: Investment and Manufacturing - The company is committed to a $55 billion investment in U.S. manufacturing, research and development, and technology by early 2029, with billions already initiated in the last 10 months [3][4]. - As part of this investment, Johnson & Johnson is establishing two new U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product facility in North Carolina [4]. - A $2 billion biologics manufacturing facility is under construction in Wilson, North Carolina, expected to create approximately 5,000 skilled jobs [5]. - The company has secured a new 160,000+ square foot biopharmaceutical manufacturing site in Holly Springs, North Carolina, with a $2 billion commitment over the next 10 years, creating around 120 new jobs [6]. Group 2: Access and Pricing - Johnson & Johnson is participating in TrumpRx.gov, a platform that allows American patients to purchase medicines at significantly discounted rates [8]. - The company aims to enable American patients to access medicines at prices comparable to those in other developed countries and provide Medicaid program access at similar pricing [8].

This audio is auto-generated. Please let us know if you have feedback Dive Brief:Children’s apparel brand Hanna Andersson appointed Kacey Sharrett as its chief digital officer, the company announced Monday. Sharrett reports to CEO Aimée Lapic, according to a company spokesperson. Sharrett will steer the company’s digital strategy and customer experience, using its digital presence to drive customer engagement, acquisition and loyalty. Sharrett most recently served as head of direct to consumer at GoPro, wh ...

Core Viewpoint - Johnson & Johnson (JNJ) is set to announce its fourth-quarter and full-year 2025 results, with a focus on the performance of its Innovative Medicine segment, which includes various blockbuster therapies across multiple disease areas [1] Group 1: Sales Performance - The Innovative Medicine segment experienced a 3.4% organic sales growth in the first nine months of 2025, despite the loss of exclusivity for its multi-billion-dollar product, Stelara [2][10] - The segment recorded over $15 billion in sales for two consecutive quarters, indicating resilience despite the challenges posed by Stelara's loss of exclusivity [2] - JNJ anticipates growth in Q4 driven by increased sales of key products like Darzalex, Tremfya, and Erleada, alongside the rapid adoption of new drugs such as Carvykti and Tecvayli [3][10] Group 2: Competitive Landscape - The launch of several biosimilar versions of Stelara in 2025 has negatively impacted the Innovative Medicines segment's growth, contributing to a decline of 1070 basis points in Q3 [5] - Rising competition in the U.S. market, particularly from new oral therapies, is expected to adversely affect sales of Imbruvica [6] - The redesign of Medicare Part D under the Inflation Reduction Act is also impacting sales of several drugs, including Stelara and Imbruvica [6] Group 3: Future Outlook - Initial sales figures for JNJ's newly approved drug, Imaavy, are anticipated, as it was approved for treating generalized myasthenia gravis in the U.S. and EU [7] - The Innovative Medicines unit is projected to have a compound annual growth rate (CAGR) of around 5% over the next three years [7] Group 4: Competitive Positioning - JNJ's key areas of focus include immunology and oncology, with significant competition from other large drugmakers such as Novartis, AstraZeneca, and AbbVie in oncology, and AbbVie and Amgen in immunology [8] Group 5: Valuation and Performance - JNJ's shares have outperformed the industry over the past year, with a 45.9% increase compared to an 18.4% rise for the industry [11] - The company's shares are currently trading at a price/earnings ratio of 18.03, slightly above the industry average of 17.54 and its five-year mean of 15.65 [12]